FLUNITY-HD
The FLUNITY-HD Study is the largest individually randomized influenza vaccine effectiveness study and the first of its kind for an influenza vaccine.
The study demonstrates the superior benefit of HD-IIV, specifically developed for older adults, compared with SD-IIV against a wide range of hospitalization outcomes in a prespecified and powered analysis encompassing nearly half a million participants. Providing the high-quality data, this study provides further critical evidence that widespread use of HD-IIV could substantially reduce the burden of influenza on both older adults and healthcare systems globally.
FLUNITY-HD Study Definitively Demonstrated the Superior Protection Beyond Flu of High-Dose Flu Vaccine vs Standard-Dose Flu
FLUNITY-HD is the largest ever individually randomised influenza vaccine effectiveness study, with nearly half a million older adults across multiple seasons
FLUNITY-HD joins a growing body of data demonstrating the superiority of high-dose vaccine
Make high-dose flu vaccine your choice for protection beyond flu.
FLUNITY-HD: Expanding Protection Beyond Flu
This GROUNDBREAKING STUDY adds to the vast body of evidence showing the superior protection beyond flu of high-dose flu vaccine
|
The ONLY high-dose flu vaccine to demonstrate superior protection against both flu infection and its complications in robust, individually randomised studies† |
|
Over 15 years of evidence in more than 45 million older adults |
|
A well-established safety profile |
FLUNITY-HD provides public health decision-makers and healthcare professionals the clinical confidence needed to recommend high-dose flu vaccine for older adults,‡ and to make informed choices for patients and their families
*DANFLU-2 covered the 2022-2023, 2023-2024, and 2024-2025 seasons, and GALFLU covered the 2023-2024 and 2024-2025 seasons.
†The individually randomised studies are the pivotal trial of high-dose flu vaccine and FLUNITY-HD.
‡According to indication and local recommendation.
Prof. Tor explaining FLUNITY-HD data
FLUNITY-HD Cardiovascular Outcomes
HD-IIV consistently reduced severe hospitalization outcomes compared with SD-IIV regardless of prior history of CVD. Among specific CV outcomes1, HD-IIV conferred a particularly substantial benefit against hospitalization for HF compared with SD-IIV.1 Moreover, another prespecified analysis supports the use of HD-IIV for reducing both influenza specific and other hospitalization outcomes in older individuals both with and without preexisting ASCVD, with potentially greater absolute benefit among individuals with ASCVD. 2